Intercepting pancreatic cancer development with mutant KRAS-targeted immunotherapy

被引：2
|
作者：
Zaidi, Neeha
Huff, Amanda
Marcisak-Davis, Emily
Haldar, Daniel
Heumann, Thatcher
Konig, Max
Mog, Brian
Montagne, Janelle
Longway, Gabriella
Andaloori, Lalitya
Lyman, Melissa
Danilova, Ludmila
Nauroth, Julie
Kagohara, Luciane
Fertig, Elana
Azad, Nilo
Jaffee, Elizabeth
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 22期
关键词：
D O I：
10.1158/1538-7445.PANCA22-IA013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IA013
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS
    Duan, Xiaohua
    Zhang, Tuo
    Feng, Lingling
    de Silva, Neranjan
    Greenspun, Benjamin
    Wang, Xing
    Moyer, Jenna
    Martin, M. Laura
    Chandwani, Rohit
    Elemento, Olivier
    Leach, Steven D.
    Evans, Todd
    Chen, Shuibing
    Pan, Fong Cheng
    CELL STEM CELL, 2024, 31 (01) : 71 - 88.e8
  • [42] Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?
    Gillson, Josef
    Ramaswamy, Yogambha
    Singh, Gurvinder
    Gorfe, Alemayehu A.
    Pavlakis, Nick
    Samra, Jaswinder
    Mittal, Anubhav
    Sahni, Sumit
    CANCERS, 2020, 12 (05)
  • [43] Targeting ALDH1A1 to enhance the efficacy of KRAS-targeted therapy through ferroptosis
    Bian, Yunyi
    Shan, Guangyao
    Bi, Guoshu
    Liang, Jiaqi
    Hu, Zhengyang
    Sui, Qihai
    Shi, Haochun
    Zheng, Zhaolin
    Yao, Guangyu
    Wang, Qun
    Fan, Hong
    Zhan, Cheng
    REDOX BIOLOGY, 2024, 77
  • [44] KRAS and clinical context: Differential dynamic signaling output of KRAS mutant lung, colorectal and pancreatic cancer cell lines when exposed to targeted anticancer drugs
    Stewart, Adam
    Coker, Elizabeth
    Minchom, Anna
    Thavasu, Parames
    Georgiou, Alexandros
    Sadanandam, Anguraj
    Yap, Timothy A.
    de Bono, Johann S.
    Al-Lazikani, Bissan
    Banerji, Udai
    CANCER RESEARCH, 2016, 76
  • [45] Combination inhibitor strategies targeting KRAS effector signaling in KRAS-mutant pancreatic cancer.
    Ozkan-Dagliyan, Irem
    Goodwin, Craig M.
    Bryant, Kirsten L.
    George, Samuel D.
    Lucas, Kelly
    Gautam, Prson
    Wennerberg, Krister
    Cox, Adrienne D.
    Der, Channing J.
    MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 68 - 68
  • [46] Nano-Targeted Kinase Inhibitor Treatment of KRAS Mutant Lung Cancer
    Sridharan, Ramya
    Shah, Janki
    Shamay, Yosef
    Heller, Daniel
    FASEB JOURNAL, 2018, 32 (01):
  • [47] Development of targeted therapies for pancreatic cancer
    Philip, Philip A.
    LANCET ONCOLOGY, 2011, 12 (03): : 206 - 207
  • [48] Development and characterisation of KRASmulti inhibitors for the treatment of KRAS mutant pancreatic ductal adenocarcinoma
    Tedeschi, Antonio
    Schaaf, Otmar
    Gmachl, Michael
    Herdeis, Lorenz
    Rocchetti, Francesca
    Popow, Johannes
    Schischlik, Fiorella
    Gerlach, Daniel
    Lipp, Jesse
    Broker, Joachim
    Mantoulidis, Andreas
    Smethurst, Chris
    Kessler, Dirk
    Boettcher, Jark
    Wunberg, Tobias
    Santoro, Valeria
    Waterson, Alex
    Phan, Jason
    Little, Andrew
    Abbott, Jason
    Sun, Qi
    Fesik, Stephen
    Mcconnell, Darryl
    Pearson, Mark A.
    Kraut, Norbert
    Rudolph, Dorothea
    CANCER RESEARCH, 2024, 84 (02)
  • [49] Development of siRNA Payloads to Target KRAS-Mutant Cancer
    Yuan, Tina L.
    Fellmann, Christof
    Lee, Chih-Shia
    Ritchie, Cayde D.
    Thapar, Vishal
    Lee, Liam G.
    Hsu, Dennis J.
    Grace, Danielle
    Carver, Joseph O.
    Zuber, Johannes
    Luo, Ji
    McCormick, Frank
    Lowe, Scott W.
    CANCER DISCOVERY, 2014, 4 (10) : 1182 - 1197
  • [50] KRAS in Pancreatic Cancer
    Agarwal, Archana
    Saif, Muhammad Wasif
    JOURNAL OF THE PANCREAS, 2014, 15 (04): : 303 - 305
12345